Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis

Cen Xie, Tomoki Yagai, Yuhong Luo, Xianyi Liang, Tao Chen, Qiong Wang, Dongxue Sun, Jie Zhao, Sadeesh K. Ramakrishnan, Lulu Sun, Chunmei Jiang, Xiang Xue, Yuan Tian, Kristopher W. Krausz, Andrew D. Patterson, Yatrik M. Shah, Yue Wu, Changtao Jiang, Frank J. Gonzalez

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease is becoming the most common chronic liver disease in Western countries, and limited therapeutic options are available. Here we uncovered a role for intestinal hypoxia-inducible factor (HIF) in hepatic steatosis. Human-intestine biopsies from individuals with or without obesity revealed that intestinal HIF-2α signaling was positively correlated with body-mass index and hepatic toxicity. The causality of this correlation was verified in mice with an intestine-specific disruption of Hif2a, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower as compared to control mice. PT2385, a HIF-2α-specific inhibitor, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF-2α. Intestine HIF-2α inhibition markedly reduced intestine and serum ceramide levels. Mechanistically, intestine HIF-2α regulates ceramide metabolism mainly from the salvage pathway, by positively regulating the expression of Neu3, the gene encoding neuraminidase 3. These results suggest that intestinal HIF-2α could be a viable target for hepatic steatosis therapy.

Original languageEnglish (US)
Pages (from-to)1298-1308
Number of pages11
JournalNature Medicine
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Intestines
Obesity
Chemical activation
Liver
Ceramides
Salvaging
Gene encoding
Biopsy
Neuraminidase
High Fat Diet
Therapeutic Uses
Nutrition
Metabolism
Causality
Toxicity
endothelial PAS domain-containing protein 1
Liver Diseases
Body Mass Index
Chronic Disease
Fats

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Xie, C., Yagai, T., Luo, Y., Liang, X., Chen, T., Wang, Q., ... Gonzalez, F. J. (2017). Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nature Medicine, 23(11), 1298-1308. https://doi.org/10.1038/nm.4412
Xie, Cen ; Yagai, Tomoki ; Luo, Yuhong ; Liang, Xianyi ; Chen, Tao ; Wang, Qiong ; Sun, Dongxue ; Zhao, Jie ; Ramakrishnan, Sadeesh K. ; Sun, Lulu ; Jiang, Chunmei ; Xue, Xiang ; Tian, Yuan ; Krausz, Kristopher W. ; Patterson, Andrew D. ; Shah, Yatrik M. ; Wu, Yue ; Jiang, Changtao ; Gonzalez, Frank J. / Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. In: Nature Medicine. 2017 ; Vol. 23, No. 11. pp. 1298-1308.
@article{51cef56841f14a199e64418333c8f0e1,
title = "Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis",
abstract = "Nonalcoholic fatty liver disease is becoming the most common chronic liver disease in Western countries, and limited therapeutic options are available. Here we uncovered a role for intestinal hypoxia-inducible factor (HIF) in hepatic steatosis. Human-intestine biopsies from individuals with or without obesity revealed that intestinal HIF-2α signaling was positively correlated with body-mass index and hepatic toxicity. The causality of this correlation was verified in mice with an intestine-specific disruption of Hif2a, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower as compared to control mice. PT2385, a HIF-2α-specific inhibitor, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF-2α. Intestine HIF-2α inhibition markedly reduced intestine and serum ceramide levels. Mechanistically, intestine HIF-2α regulates ceramide metabolism mainly from the salvage pathway, by positively regulating the expression of Neu3, the gene encoding neuraminidase 3. These results suggest that intestinal HIF-2α could be a viable target for hepatic steatosis therapy.",
author = "Cen Xie and Tomoki Yagai and Yuhong Luo and Xianyi Liang and Tao Chen and Qiong Wang and Dongxue Sun and Jie Zhao and Ramakrishnan, {Sadeesh K.} and Lulu Sun and Chunmei Jiang and Xiang Xue and Yuan Tian and Krausz, {Kristopher W.} and Patterson, {Andrew D.} and Shah, {Yatrik M.} and Yue Wu and Changtao Jiang and Gonzalez, {Frank J.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1038/nm.4412",
language = "English (US)",
volume = "23",
pages = "1298--1308",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",

}

Xie, C, Yagai, T, Luo, Y, Liang, X, Chen, T, Wang, Q, Sun, D, Zhao, J, Ramakrishnan, SK, Sun, L, Jiang, C, Xue, X, Tian, Y, Krausz, KW, Patterson, AD, Shah, YM, Wu, Y, Jiang, C & Gonzalez, FJ 2017, 'Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis', Nature Medicine, vol. 23, no. 11, pp. 1298-1308. https://doi.org/10.1038/nm.4412

Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. / Xie, Cen; Yagai, Tomoki; Luo, Yuhong; Liang, Xianyi; Chen, Tao; Wang, Qiong; Sun, Dongxue; Zhao, Jie; Ramakrishnan, Sadeesh K.; Sun, Lulu; Jiang, Chunmei; Xue, Xiang; Tian, Yuan; Krausz, Kristopher W.; Patterson, Andrew D.; Shah, Yatrik M.; Wu, Yue; Jiang, Changtao; Gonzalez, Frank J.

In: Nature Medicine, Vol. 23, No. 11, 01.11.2017, p. 1298-1308.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis

AU - Xie, Cen

AU - Yagai, Tomoki

AU - Luo, Yuhong

AU - Liang, Xianyi

AU - Chen, Tao

AU - Wang, Qiong

AU - Sun, Dongxue

AU - Zhao, Jie

AU - Ramakrishnan, Sadeesh K.

AU - Sun, Lulu

AU - Jiang, Chunmei

AU - Xue, Xiang

AU - Tian, Yuan

AU - Krausz, Kristopher W.

AU - Patterson, Andrew D.

AU - Shah, Yatrik M.

AU - Wu, Yue

AU - Jiang, Changtao

AU - Gonzalez, Frank J.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Nonalcoholic fatty liver disease is becoming the most common chronic liver disease in Western countries, and limited therapeutic options are available. Here we uncovered a role for intestinal hypoxia-inducible factor (HIF) in hepatic steatosis. Human-intestine biopsies from individuals with or without obesity revealed that intestinal HIF-2α signaling was positively correlated with body-mass index and hepatic toxicity. The causality of this correlation was verified in mice with an intestine-specific disruption of Hif2a, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower as compared to control mice. PT2385, a HIF-2α-specific inhibitor, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF-2α. Intestine HIF-2α inhibition markedly reduced intestine and serum ceramide levels. Mechanistically, intestine HIF-2α regulates ceramide metabolism mainly from the salvage pathway, by positively regulating the expression of Neu3, the gene encoding neuraminidase 3. These results suggest that intestinal HIF-2α could be a viable target for hepatic steatosis therapy.

AB - Nonalcoholic fatty liver disease is becoming the most common chronic liver disease in Western countries, and limited therapeutic options are available. Here we uncovered a role for intestinal hypoxia-inducible factor (HIF) in hepatic steatosis. Human-intestine biopsies from individuals with or without obesity revealed that intestinal HIF-2α signaling was positively correlated with body-mass index and hepatic toxicity. The causality of this correlation was verified in mice with an intestine-specific disruption of Hif2a, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower as compared to control mice. PT2385, a HIF-2α-specific inhibitor, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF-2α. Intestine HIF-2α inhibition markedly reduced intestine and serum ceramide levels. Mechanistically, intestine HIF-2α regulates ceramide metabolism mainly from the salvage pathway, by positively regulating the expression of Neu3, the gene encoding neuraminidase 3. These results suggest that intestinal HIF-2α could be a viable target for hepatic steatosis therapy.

UR - http://www.scopus.com/inward/record.url?scp=85033220110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033220110&partnerID=8YFLogxK

U2 - 10.1038/nm.4412

DO - 10.1038/nm.4412

M3 - Article

C2 - 29035368

AN - SCOPUS:85033220110

VL - 23

SP - 1298

EP - 1308

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 11

ER -